

Addiction Medicine

The Official Journal of the American Society of Addiction Medicine

Richard Saitz, MD, MPH

Boston University School of Public Health

- Spectrum of unhealthy substance use
- Alcohol use and alcohol use disorder
- Integration of addiction and other healthcare
- Accurate terminology

Kelly E. Dunn, PhD

Johns Hopkins University School of Medicine

- Opioid use disorder, treatment, and comorbidities
- Alcohol use disorder and treatment
- Tobacco use and cessation
- Incentive-based treatments
- Individual differences
- Healthcare systems

Ismene Petrakis, MD

Yale University School of Medicine

- Opioid use disorder
- Psychiatric comorbidity
- Neurobiology
- Alcohol
- Psychopharmacology

Martha J. Wunsch, MD, FAAP, DFASAM

Kaiser Permanente Northern California

- Women and substance-exposed newborns
- Adolescent substance use disorder
- Pharmacological treatments
- Opioid overdose and treatment
- Epidemiology
- Prescription drug abuse

Frank J. Vocci, PhD

Friends Research

- Medication development
- Medical consequences
- HIV, AIDS, hepatitis C
- Opioids
- Stimulants
- Tobacco

Debbie M. Cheng, ScD

Boston University School of Public Health

- Biostatistics
- Longitudinal data analyses
- Design and analysis of clinical trials
- HIV

Charles Maynard, PhD

University of Washington

- Statistics
- Clinical trials
- Public health
- Policy
- Military
- Epidemiology

Katie Witkiewitz, PhD

University of New Mexico

- Statistical methods
- Empirically supported treatments for addiction
- Mechanisms of behavior change
- Addictive behavior relapse
- Mindfulness-based and group-based relapse prevention

Robert M. Anthenelli, MD

University of California, San Diego

- Cigarette smoking
- Alcohol
- Neurobiology
- Comorbidity
- Stress
- Sex differences

Gary Aston-Jones, PhD

Rutgers University and Rutgers Behavioral and Health Sciences

- Reward behavior
- Cognitive function
- Neurobiology and neurophysiology
- Neuroanatomy
- Behavioral pharmacology
- Animal models

Yatan Pal Singh Balhara, MD, DNB (Psychiatry), MNAMS, MSc

All India Institute of Medical Sciences, New Delhi, India

- Mental health policy and services
- Comorbidity
- “Dual” diagnosis
- Behavioral/process addictions (Internet, gambling)

- eHealth

Robert L. Balster, PhD

Virginia Commonwealth University

- Drug addictive potential assessment
- Medication development
- Tobacco regulatory science
- Training

Kathleen T. Brady, MD, PhD

Medical University Of South Carolina

- Addiction psychiatry
- Gender and substance use disorders
- Pharmacotherapy of substance use disorders
- Comorbidity
- PTSD and other anxiety disorders

Karen L. Cropsey, PsyD

University of Alabama at Birmingham

- Tobacco
- Criminal justice
- HIV
- Opioids
- Treatment adherence

James L. Ferguson, DO, DFASAM

Recovery Management Solutions

- Forensic toxicology
- Medical Review Officer

David A. Fiellin, MD

Yale University

- Treatment strategies
- Opioid use disorder medication treatment
- Office-based, primary care, emergency department, and HIV specialty settings

Michael Fingerhood MD, FACP, FASAM, AAHIVS

Johns Hopkins University

- Medical complications of addiction, including HIV and HCV
- Alcohol
- Older adults and substance use disorders
- Buprenorphine
- Withdrawal management
- Ethical issues

Catherine Friedman, MD

Brown University

- Education
- Child and adolescent psychiatry
- Dual diagnosis
- Parenting, pregnancy, and addictions
- Women, addictions, and other psychiatric disorders
- Opioid use and cooccurring disorders

John A. Fromson, MD

Harvard Medical School

- Physician and medical student health
- Professional development
- Patient safety
- Physician monitoring

Marc Galanter, MD, MPH, DFASAM

New York University

- Family therapy
- Pharmacological treatment strategies
- Twelve-Step

Marc N. Gourevitch, MD, MPH, DFASAM

New York University School of Medicine

- Health service utilization and delivery systems
- Epidemiology and population health, including underserved populations
- Pharmacological treatments
- Primary care and public sector initiatives
- Translation from research to clinical application

Nady El Guebaly, MD, DPsych, DFASAM

University of Calgary

- Alcohol
- Gambling
- Substance use disorder education and training
- Comorbid substance use disorders
- Treatment programs

Kyle Kampman, MD, DFASAM

University of Pennsylvania

- Alcohol
- Cocaine
- Opioids
- Withdrawal syndrome
- Pharmacological treatments
- Psychotherapy

Jag Khalsa, MS, PhD

Formerly, Chief, Medical Consequences of Drug Abuse and Infections Branch, National Institute on Drug Abuse

Currently, Special Volunteer at NIDA/NIH

- Clinical research on medical and health consequences of drug use
- Comorbid viral infection (HIV, HCV)
- Drug development
- Cannabis/Medicinal cannabis

Barbara J. Mason, PhD

The Scripps Research Institute

- Medication development for protracted abstinence and relapse prevention
- Alcohol, cannabis and cigarettes
- Proof-of-concept early-phase human laboratory studies
- Double-blind, placebo-controlled clinical efficacy studies

Jane C. Maxwell, PhD

University of Texas Austin

- Epidemiology and patterns of use and emergence of drug trends
- Methamphetamine
- Black tar heroin
- Synthetic and new psychoactive drugs
- Methadone mortality
- Use of multiple data sources to identify new drug trends

Mark Potenza, MD, PhD

Yale University

- Neurobiology
- Addictions
- Impulse control
- Gambling

Gary M. Reisfield, M.D.

University of Florida College of Medicine

- Cannabis and other drugs
- Pharmacological treatment prescribers/pharmacy
- Drug monitoring programs
- Drug screening
- Pain
- Toxicology

Perry F. Renshaw, MD, PhD

University of Utah

- Imaging
- Neurochemistry

- Mood disorders
- Natural products as treatment strategies

Richard K. Ries, MD, DFASAM

University of Washington

- Suicide
- Medication management –Psychiatric and/or Addiction
- Mental healthcare
- Psychiatry
- 12 Step, other “self help” recovery

David E. Smith, MD, DFASAM

University of California at San Francisco

- Adolescent addiction
- Cannabis
- Toxicology
- Psychedelic misuse

Jon E. Sprague, PhD

Ohio Northern University

- Amphetamines
- Drug design
- Pharmacokinetics
- Bath salts
- MDMA
- Pharmacogenetics

Eric Strain, MD

Johns Hopkins School of Medicine

- Opioids
- Cannabis
- Alcohol
- Harm reduction and psychosocial factors
- Medication treatment
- Psychiatric comorbidity

Mishka Terplan, MD, MPH, FACOG, DFASAM

Virginia Commonwealth University

- Obstetrics and gynecology
- Harm reduction
- Public health
- Health disparities and stigma
- Gender and addiction

Nassima Ait-Daoud Tiouririne, MD

University of Virginia

- Medication development
- Biological and psychosocial factors
- Transcranial magnetic stimulation
- Depression and Psychiatry services

Michael F. Weaver, MD, DFASAM

The University of Texas Health Science Center at Houston

- Opioids
- Alcohol
- Opioid agonist therapy (buprenorphine, methadone)
- Prescription medication misuse
- Alcohol withdrawal
- Ethics

Joseph Westermeyer, MD, PhD, DFASAM

Minneapolis VAMC

- Psychiatric epidemiology
- Psychopathology across cultures
- Treatment outcome
- Trajectory of addiction with and without treatment
- Public health aspects (prevention, early intervention, social interventions, economic consequences)
- High-risk subgroups, comorbidities

George E. Woody, MD, DFASAM

University of Pennsylvania

- Substance use disorder treatment outcomes
- “Dual” diagnosis
- HIV risk reduction

Li-Tzy Wu, ScD, RN, MA

School of Medicine, Duke University Medical Center

- Opioids, Cannabis, Alcohol, Tobacco, Hallucinogens, Stimulants
- Pain, Medical Comorbidity
- Clinical trials
- Screening and brief intervention
- Health and pharmacy services research and healthcare integration
- Psychometric analysis and research design/methods
- Epidemiology

Nickolas D. Zaller, PhD

University of Arkansas for Medical Sciences

- Criminal justice
- Infectious diseases and HIV risk
- Opioids
- Injection drug use

- Harm reduction